- Home
- ANIX vs QNCX Comparison
ANIX vs QNCX Comparison
Compare ANIX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- QNCX
- Stock Information
- Founded
- ANIX 1982
- QNCX 2012
- Country
- ANIX United States
- QNCX United States
- Employees
- ANIX N/A
- QNCX N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- QNCX Health Care
- Exchange
- ANIX Nasdaq
- QNCX Nasdaq
- Market Cap
- ANIX 95.7M
- QNCX 90.8M
- IPO Year
- ANIX 1987
- QNCX 2019
- Fundamental
- Price
- ANIX $2.94
- QNCX $1.60
- Analyst Decision
- ANIX Strong Buy
- QNCX Strong Buy
- Analyst Count
- ANIX 3
- QNCX 6
- Target Price
- ANIX $9.00
- QNCX $8.00
- AVG Volume (30 Days)
- ANIX 64.6K
- QNCX 124.9K
- Earning Date
- ANIX 09-10-2025
- QNCX 11-12-2025
- Dividend Yield
- ANIX N/A
- QNCX N/A
- EPS Growth
- ANIX N/A
- QNCX N/A
- EPS
- ANIX N/A
- QNCX N/A
- Revenue
- ANIX N/A
- QNCX N/A
- Revenue This Year
- ANIX N/A
- QNCX N/A
- Revenue Next Year
- ANIX N/A
- QNCX N/A
- P/E Ratio
- ANIX N/A
- QNCX N/A
- Revenue Growth
- ANIX N/A
- QNCX N/A
- 52 Week Low
- ANIX $2.07
- QNCX $0.69
- 52 Week High
- ANIX $4.20
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ANIX 43.29
- QNCX 47.89
- Support Level
- ANIX $2.93
- QNCX $1.56
- Resistance Level
- ANIX $3.09
- QNCX $1.65
- Average True Range (ATR)
- ANIX 0.11
- QNCX 0.08
- MACD
- ANIX 0.00
- QNCX 0.00
- Stochastic Oscillator
- ANIX 1.85
- QNCX 64.65
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.